文献速递瓣膜外科

中危患者中自膨胀式经导管主动脉瓣的成本效果

Cost-Effectiveness of Self-Expandable Transcatheter Aortic Valves in Intermediate-Risk Patients.
PubMed 文献 · Ann Thorac Surg · 2018-05-03

基于加拿大医疗系统支付方视角的成本效用分析,采用马尔可夫模型模拟中危患者终身成本与质量调整生命年(QALY),比较自膨胀式经导管主动脉瓣置换(TAVR)与外科主动脉瓣置换(SAVR)。TAVR组终身成本为44,299±7,260加元,SAVR组为32,994±13,434加元;TAVR组获得6.42±1.33 QALY,SAVR组为6.28±1.32 QALY;增量成本11,305加元,增量效果0.15 QALY,增量成本效果比(ICER)为76,736加元/QALY。结论认为自膨胀式TAVR具有成本效果,但存在中度不确定性。

要点

  • 中危患者中,自膨胀式TAVR相比SAVR增量成本为11,305加元,增量效果为0.15 QALY。
  • ICER为76,736加元/QALY;概率分析中分别有52.8%和57.2%的模拟低于50,000和100,000加元/QALY的支付意愿阈值。
  • 当TAVR瓣膜系统价格为17,397加元(基础案例为22,000加元)时,在50,000加元/QALY阈值下TAVR具有成本效果。

核心结论

  • 自膨胀式TAVR被认为具有成本效果,但存在中度不确定性,反映了数据非劣效的性质。

研究设计与样本

  • 从加拿大医疗系统支付方视角进行的成本效用分析,构建终身概率马尔可夫模型比较自膨胀式TAVR与SAVR,成本和效果按每年1.5%贴现,效果数据来自Surgical Replacement and Transcatheter Aortic Valve Implantation试验,成本主要来自加拿大健康信息研究所。

主要发现

  • 基础案例分析中,TAVR组终身总成本为44,299±7,260加元,SAVR组为32,994±13,434加元。
  • TAVR组总效果为6.42±1.33 QALY,SAVR组为6.28±1.32 QALY。
  • TAVR相比SAVR的增量成本为11,305加元,增量效果为0.15 QALY,ICER为76,736加元/QALY。
  • 概率分析显示中度不确定性,分别有52.8%和57.2%的模拟低于50,000和100,000加元/QALY的支付意愿阈值。
  • 敏感性分析中,当TAVR瓣膜系统价格为17,397加元(基础案例为22,000加元)时,在50,000加元/QALY支付意愿阈值下TAVR具有成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A recent clinical trial showed that self-expandable transcatheter aortic valve replacement (TAVR) was non-inferior to surgical aortic valve replacement (SAVR). However, the cost-effectiveness of self-expandable TAVR in the intermediate-risk population remains unknown. METHODS: A cost-utility analysis from the Canadian health care system payer's perspective was undertaken to compare self-expandable TAVR with SAVR. A fully probabilistic Markov model over the patient's lifetime was constructed to estimate differences in costs (2016 Canadian dollars) and effectiveness (quality-adjusted life-years [QALYs]), discounted at 1.5% per annum. Incremental cost-effectiveness ratios (ICERs) were calculated. Efficacy inputs were obtained from the Surgical Replacement and Transcatheter Aortic Valve Implantation trial, and costs were primarily obtained from the Canadian Institute of Health Information. Probabilistic analysis (PA) and one-way deterministic sensitivity analyses were conducted around key point estimates to address uncertainty. RESULTS: In the base case analysis, with discounting, the total lifetime costs (mean ± standard deviation) in the TAVR and SAVR arms were $44,299 ± $7,260 and $32,994 ± $13,434, respectively, whereas total effectiveness values were 6.42 ± 1.33 QALYs and 6.28 ± 1.32 QALYs, respectively. This yielded an incremental cost of $11,305 and incremental effectiveness of 0.15 QALYs when TAVR was compared with SAVR for an ICER of $76,736/QALY. In the PA, there was moderate uncertainty, with 52.8% and 57.2% of simulations less than willingness-to-pay thresholds of $50,000 and $100,000, respectively. In the sensitivity analysis, when the cost of TAVR valve system was priced at $17,397 (base case $22,000 Canadian dollars), TAVR was found to be cost-effective at a willingness-to-pay threshold of $50,000/QALY. CONCLUSIONS: Self-expandable TAVR was found to be cost-effective; however, there was moderate uncertainty, reflecting the non-inferiority nature of the data.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Tam DY, Hughes A, Wijeysundera HC, et al. Cost-Effectiveness of Self-Expandable Transcatheter Aortic Valves in Intermediate-Risk Patients. Ann Thorac Surg. 2018. PMID: 29730344. doi:10.1016/j.athoracsur.2018.03.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。